CJC-1295 (No DAC) and Ipamorelin: A Research Overview of the Combination

The pairing of CJC-1295 (no DAC) with ipamorelin is one of the most frequently studied dual-mechanism designs in growth-hormone-axis research. The reason is not marketing — it is pharmacology. The two compounds act on distinct receptor systems that both contribute to growth hormone release, and combining them has been reported to yield more than the sum of the parts. That is a genuinely interesting research question, separate from any claim about what the combination does for a person.

This overview summarizes what the published literature reports about each peptide, the rationale for combining them, the shape of the evidence, and — importantly — the safety and regulatory considerations specific to these compounds. Throughout, it describes what studies observed in their experimental systems. It is not dosing guidance, medical advice, or a recommendation for use.

The Two Components

CJC-1295 (no DAC). This is a synthetic analog of growth hormone-releasing hormone (GHRH), also called Modified GRF 1-29. It binds the GHRH receptor on pituitary somatotroph cells and stimulates the synthesis and release of growth hormone. The “no DAC” designation distinguishes it from the longer-acting CJC-1295 with DAC (Drug Affinity Complex), which binds albumin and has a half-life measured in days; the no-DAC form clears within roughly half an hour, producing a brief, sharp GH pulse rather than sustained elevation (mechanism overview, JCEM-cited summary). That short half-life is exactly why the no-DAC version is the one typically paired with ipamorelin in research protocols.

Ipamorelin. This is a pentapeptide growth hormone secretagogue (a GHRP-class compound) that acts on a different target: the ghrelin receptor, GHS-R1a. It is noted in the literature for its selectivity — compared with older GHRPs such as GHRP-2 and GHRP-6, ipamorelin is reported to stimulate GH release with comparatively little effect on cortisol and prolactin (GHRH/GHRP mechanism review). That selectivity is the main reason it is favored over earlier secretagogues in combination studies.

The Rationale for Combining Them

The logic of the pairing rests on the architecture of the somatotroph cell, which carries both receptor types. GHRH-pathway activation (via CJC-1295) and ghrelin-pathway activation (via ipamorelin) engage separate, non-competing intracellular signaling routes that both converge on growth hormone release.

When both pathways are stimulated simultaneously, the GH response reported in studies exceeds that produced by either compound alone. This “GHRH + GHRP synergy” is not new — foundational endocrinology work by Bowers and colleagues showed that combined submaximal doses of GHRH and GHRP produced GH release greater than the additive effect. Later infusion studies reported combined GH secretion severalfold higher than that of either agent alone (synergy and combination evidence summary). A useful way to frame the design: CJC-1295 raises the baseline responsiveness of the pituitary, and ipamorelin triggers a selective pulse on top of it.

The Evidence Base — and What It Does Not Cover

Two things are true at once here, and keeping them apart is essential.

On one hand, the individual mechanisms are well characterized, and there is real human pharmacology data on the components. A published clinical study of CJC-1295 (the DAC version) in healthy adults reported dose-dependent increases in growth hormone and IGF-1 sustained for several days after a single injection (Teichman et al., JCEM, summarized). The receptor-level synergy of the GHRH+GHRP approach is similarly well documented in the endocrinology literature.

On the other hand, there is no body of large, controlled clinical trials testing the specific CJC-1295-no-DAC-plus-ipamorelin combination as a therapy with defined outcomes, dosing, and long-term safety in a general population. Much of what circulates as a combination “protocol” derives from preclinical work, the pharmacology of the separate components, and community practice — not from completed trials of the blend itself. Mechanistic plausibility and short-term pharmacology are not the same as demonstrated clinical efficacy and safety.

Safety Considerations Specific to These Compounds

This combination warrants a more pointed safety note than some other research peptides, for two documented reasons. First, in a Phase II trial of CJC-1295 (DAC) in 192 patients with HIV-associated lipodystrophy, one death from a myocardial infarction was recorded (safety-data summary). Whether the drug caused that event is not established — single events in trial populations with underlying conditions are difficult to attribute — but it is part of the safety record and should be represented honestly rather than omitted.

Second, the FDA has flagged specific risks associated with these peptides. In its review materials, the agency noted concerns, including immunogenicity — the potential for the body to mount an immune response, with serious reactions possible — and, for CJC-1295, cardiovascular effects such as increased heart rate and vasodilatory reactions (FDA PCAC briefing document). There is also a general pharmacological caution that applies to any sustained elevation of the GH/IGF-1 axis: chronically elevated IGF-1 raises theoretical concerns about abnormal cell growth. These are reasons the compounds are studied carefully, not casually.

Regulatory and Anti-Doping Status

The status below reflects mid-2026 and is in flux; verify against current FDA notices before relying on it. Neither CJC-1295 (in any form) nor ipamorelin is FDA-approved as a drug for any indication, nor is either a component of an approved drug. Their compounding status has been unsettled: both were placed in the FDA’s Category 2 (“significant safety concerns”) on the interim 503A bulks list, but legal challenges suspended enforcement, and the FDA has not finalized whether they will appear on the 503A bulks list (compounding status overview). “In flux” is the accurate description; “approved” is not, and even a favorable compounding decision would not equal FDA drug approval.

The anti-doping status is clearer and stricter. Because growth hormone secretagogues mimic the effects of human growth hormone, the World Anti-Doping Agency lists GH and GH secretagogues — including CJC-1295 — as prohibited at all times, both in and out of competition (FDA PCAC briefing document, citing the WADA prohibited list). Ipamorelin, as a GH secretagogue, is subject to the same prohibition. For any athlete subject to testing, use of this combination is a doping violation regardless of context — central information given how often these peptides are discussed in performance settings.

Why This Combination Is a Common Research Subject

Stripped of hype, the appeal is coherent. The pairing offers a well-defined, dual-receptor model of growth hormone regulation: one compound that primes the GHRH pathway, another that selectively triggers the ghrelin pathway, with a documented synergy between them and a mechanism that maps cleanly onto the body’s own pulsatile GH biology. For researchers studying the GH/IGF-1 axis, it is a logical tool. The honest summary is mechanistically well-grounded, supported by component-level human pharmacology, unproven as a combination therapy in controlled trials, flagged by the FDA for specific safety concerns, and prohibited in sport.

For deeper reading, the primary literature cited throughout this article is the best starting point. Related growth hormone secretagogue and GHRH analog topics are collected in our peptide research library, which gathers reference material on the broader class of compounds discussed here.